Neuronetics Announces Strategic Leadership Promotions to Support Future Growth
February 11 2021 - 8:00AM
Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical
technology company focused on designing, developing and marketing
products that improve the quality of life for patients who suffer
from psychiatric disorders, announced three executive leadership
team promotions to support the Company’s strategic growth plans.
Effective immediately, Steve Furlong was promoted to Senior Vice
President, Chief Financial Officer and Treasurer; Greg Harper to
Vice President, Research & Development and Clinical; and Kara
Thornton to Vice President, Human Resources. All roles report
directly to Chief Executive Officer, Keith Sullivan.
“We are fortunate to have these leaders providing strategic
guidance and championing our mission day in and day out,” said
Keith J. Sullivan, President and Chief Executive Officer of
Neuronetics. “The executive leadership team and I share the same
vision for the future of Neuronetics and I look forward to
collaborating with these individuals in their elevated roles to
drive the company forward. My sincerest congratulations to Steve,
Greg and Kara on their achievements and well-deserved
promotions.”
With more than 30 years of experience, Mr. Furlong has served as
the Company’s Vice President and Chief Financial Officer since July
2019. Prior to joining Neuronetics, Mr. Furlong served as Senior
Vice President, Finance at Metabolon and built his career working
in the financial realm of several life sciences and medical
technology companies, including Verscend Technologies, Rapid Micro
Biosystems and Hologic. He received his B.A. in Political Science
from The Pennsylvania State University and his Master of Finance
degree from Bentley University.
Mr. Harper has more than 30 years of product development
experience with global design and production teams, and has served
as the Company’s Vice President, Product Development and Operations
since September 2016. Prior to joining Neuronetics, he led Global
Computed Tomography and Research & Development as a Vice
President for Philips Healthcare and held leadership and executive
positions in the Aerospace, Healthcare, and Appliance/Lighting
businesses of GE. Mr. Harper holds a Bachelor of Science,
Electrical Engineering degree from Valparaiso University and an MBA
from the University of Wisconsin – Milwaukee.
Ms. Thornton has more than 20 years of human resources
experience in the life sciences field. She has served as the
Company’s Senior Director, Head of Human Resources since July 2019.
Prior to joining Neuronetics, Ms. Thornton served as Head of Human
Resources at Sun Pharma, where she supported the commercial and
enabling businesses across five therapeutic areas. Prior to that,
she held positions at several life sciences companies, including
DSM, Johnson and Johnson, Bayer and Daiichi Sankyo. She holds a
B.A. degree from Cabrini University in Communications and
History.
These organizational updates will allow Neuronetics to continue
its momentum, transforming lives and expanding awareness of its
NeuroStar Advanced Therapy system for those with Major Depressive
Disorder.
About NeuroneticsNeuronetics, Inc. is a
commercial-stage medical technology company focused on designing,
developing, and marketing products that improve the quality of life
for patients who suffer from psychiatric disorders. Its commercial
product, the NeuroStar® Advanced Therapy System, is a non-invasive
and non-systemic office-based treatment that uses transcranial
magnetic stimulation, or TMS, to create a pulsed, MRI-strength
magnetic field that induces electrical currents designed to
stimulate specific areas of the brain associated with mood. The
system is cleared by the United States Food and Drug
Administration, or FDA, for the treatment of major depressive
disorder in adult patients who have failed to achieve satisfactory
improvement from prior antidepressant medication in the current
episode. NeuroStar is also available in other parts of the world,
including Japan, where it is listed under Japan’s national health
insurance. Additional information can be found at
www.neuronetics.com.
Media Contact: Meagan DominickVault
Communications610-455-2779mdominick@vaultcommunications.com
Neuronetics (NASDAQ:STIM)
Historical Stock Chart
From Apr 2024 to May 2024
Neuronetics (NASDAQ:STIM)
Historical Stock Chart
From May 2023 to May 2024